JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 22, 2007; DOI: 10.1124/jpet.106.118125


0022-3565/07/3212-734-742$20.00
JPET 321:734-742, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
jpet.106.118125v1
321/2/734    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Newton, R.
Right arrow Articles by Barnes, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Newton, R.
Right arrow Articles by Barnes, P. J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*NICOTINAMIDE

INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Repression of Inflammatory Gene Expression in Human Pulmonary Epithelial Cells by Small-Molecule I{kappa}B Kinase InhibitorsFormula

Robert Newton, Neil S. Holden, Matthew C. Catley, Wale Oyelusi, Richard Leigh, David Proud, and Peter J. Barnes

Respiratory Research Group, Departments of Cell Biology and Anatomy, Physiology and Biophysics, and Medicine, University of Calgary, Calgary, Alberta, Canada (R.N., N.S.H., W.O., R.L., D.P.); and National Heart and Lung Institute, Imperial College London, London, United Kingdom (M.C.C., P.J.B.)

The airway epithelium is critical in the pathogenesis of chronic inflammatory diseases, such as asthma and chronic obstructive pulmonary disease, and, by expressing numerous inflammatory genes, plays a prominent role in disease exacerbations. Since inflammatory gene expression often involves the transcription factor nuclear factor (NF)-{kappa}B, this signaling pathway represents a site for anti-inflammatory intervention. As the airway epithelium is targeted by inhaled therapeutic agents, for example corticosteroids, human A549 pulmonary cells and primary human bronchial epithelial (HBE) cells were selected to evaluate inhibitor of {kappa}B kinase (IKK) inhibitors. In A549 cells, interleukin (IL)-1beta and tumor necrosis factor (TNF) {alpha} increased phosphorylation of I{kappa}B{alpha}, and this was followed by loss of I{kappa}B{alpha}, induction of NF-{kappa}B DNA binding, and the induction of NF-{kappa}B-dependent transcription. These events were repressed by the IKK-selective inhibitors, PS-1145 [N-(6-chloro-9H-beta-carbolin-8-ly) nicotinamide] and ML120B [N-(6-chloro-7-methoxy-9H-beta-carbolin-8-yl)-2-methyl-nicotinamide]. Inhibition of NF-{kappa}B-dependent transcription was concentration-dependent and correlated with loss of intercellular adhesion molecule (ICAM)-1 expression. Similarly, IL-1beta- and TNF{alpha}-induced expression of IL-6, IL-8, granulocyte macrophage-colony-stimulating factor (GM-CSF), regulated and activation normal T cell expressed and secreted (RANTES), growth-related oncogene {alpha}, and monocyte chemotactic protein-1 (MCP-1) was also significantly repressed. Likewise, PS-1145 and ML120B profoundly reduced NF-{kappa}B-dependent transcription induced by IL-1beta and TNF{alpha} in primary HBE cells. Parallel effects on ICAM-1 expression and a significant repression of IL-8 release were observed. In contrast, the corticosteroid, dexamethasone, was without effect on NF-{kappa}B-dependent transcription or the expression of ICAM-1. The above data provide strong support for an anti-inflammatory effect of IKK2 inhibitors acting on the pulmonary epithelium and suggest that such compounds may prove beneficial in situations where traditional corticosteroid therapies prove inadequate.


Received December 3, 2006; accepted February 20, 2007.

Address correspondence to: Dr. Robert Newton, Department of Cell Biology and Anatomy, Respiratory Research Group, Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada. E-mail: rnewton{at}ucalgary.ca




This article has been cited by other articles:


Home page
Therapeutic Advances in Respiratory DiseaseHome page
A. Zanini, A. Chetta, and D. Olivieri
Review: Therapeutic perspectives in bronchial vascular remodeling in COPD
Therapeutic Advances in Respiratory Disease, June 1, 2008; 2(3): 179 - 187.
[Abstract] [PDF]


Home page
J. Immunol.Home page
S. J. Tudhope, M. C. Catley, P. S. Fenwick, R. E. K. Russell, W. L. Rumsey, R. Newton, P. J. Barnes, and L. E. Donnelly
The Role of I{kappa}B Kinase 2, but Not Activation of NF-{kappa}B, in the Release of CXCR3 Ligands from IFN-{gamma}-Stimulated Human Bronchial Epithelial Cells
J. Immunol., November 1, 2007; 179(9): 6237 - 6245.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
Z. Bao, S. Lim, W. Liao, Y. Lin, C. Thiemermann, B. P. Leung, and W. S. F. Wong
Glycogen Synthase Kinase-3beta Inhibition Attenuates Asthma in Mice
Am. J. Respir. Crit. Care Med., September 1, 2007; 176(5): 431 - 438.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.